Alumis ALMS
NASDAQ ALMS
$6.87 +0.06 (+0.88%)
As of: Oct 22, 2026 · 9:47 AM EDT

Alumis (ALMS) Current Deferred Revenue (2025 - 2026)

Updated

Alumis' Current Deferred Revenue came in at $6.67 million for Q2 2026.

Analysis

Alumis (ALMS) Current Deferred Revenue (2025 - 2026) Analysis & Trends

At the end of FY2025, Alumis' Current Deferred Revenue was $1.46 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,148.13 Bn 1,116.72 Bn 19.71 Bn
2 Johnson & Johnson 630.09 Bn 548.62 Bn 17.26 Bn
3 AbbVie 498.99 Bn 472.10 Bn 12.70 Bn
4 Merck 374.92 Bn 329.30 Bn 12.21 Bn
5 Novartis Ag 300.99 Bn 264.98 Bn 11.24 Bn
6 Astrazeneca 264.63 Bn 238.32 Bn 12.86 Bn
7 Amgen 239.15 Bn 194.55 Bn 7.24 Bn
8 Gilead Sciences 192.23 Bn 166.43 Bn 6.22 Bn
9 Pfizer 171.17 Bn 117.82 Bn 10.94 Bn
10 Alumis 877.29 Mn -797.55 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 6.67 Mn
Dec 31, 2025 1.46 Mn
API Access

Alumis Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=ALMS&period=max&api_key=YOUR_API_KEY